Treating MS beyond no evident inflammatory activity (NEIDA): why AHSCT should be an option available to people with MS
Visit us at:
X: @aimscharity
Instagram: / aims_charity
Facebook: / aimscharity.org
Website: www.aimscharity.org
Негізгі бет Professor Gavin Giovannoni - Treating MS beyond NEIDA: why HSCT should be an option
Пікірлер